Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI analyzes 7,000 liver cancer patients to personalize care

NCT ID NCT07157085

Knowledge-focused Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study used artificial intelligence to analyze data from 7,000 liver cancer patients. The goal was to create a tool that helps doctors predict liver function, treatment outcomes, and cancer spread. The tool aims to guide personalized decisions about surgery, chemotherapy, and other treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this AI tool could help doctors choose the best treatment for each liver cancer patient, potentially improving survival.
What could go wrong
This is a completed study analyzing existing data, not a new treatment. The AI model may not work as well in other hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

7,000 people

The number who actually took part.

Started

Jan 2008

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with HCC received comprehensive therapies such as liver resection, ablation, TACE, HAIC, targeted therapy, immunotherapy and radiotherapy

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. age 18-75 years; 2. HCC diagnosed according to the European Association for the Study of the Liver/American Association for the Study of Liver Diseases criteria) 3. Eastern Cooperative Oncology Group performance status \< 2; 4. Child-Pugh class A or B liver function; Exclusion Criteria: 1. HCC combined with other malignancies; 2. missing image data during perioperative period; 3. lost to follow-up \> 12 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma (HCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma (HCC)

Contacts and locations

Locations

  • Study site

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.